intellipharm limited
intellipharm limited Company Information
Company Number
06517653
Next Accounts
255 days late
Shareholders
pankaj mansukh mahidharia
amish patel
View AllGroup Structure
View All
Industry
Management consultancy activities (other than financial management)
+1Registered Address
lynwood house, 373-375 station road, harrow, HA1 2AW
Website
www.live.intellipharm.co.ukintellipharm limited Estimated Valuation
Pomanda estimates the enterprise value of INTELLIPHARM LIMITED at £44.8k based on a Turnover of £120.4k and 0.37x industry multiple (adjusted for size and gross margin).
intellipharm limited Estimated Valuation
Pomanda estimates the enterprise value of INTELLIPHARM LIMITED at £30.3k based on an EBITDA of £10k and a 3.03x industry multiple (adjusted for size and gross margin).
intellipharm limited Estimated Valuation
Pomanda estimates the enterprise value of INTELLIPHARM LIMITED at £22k based on Net Assets of £8.9k and 2.48x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Intellipharm Limited Overview
Intellipharm Limited is a live company located in harrow, HA1 2AW with a Companies House number of 06517653. It operates in the management consultancy activities other than financial management sector, SIC Code 70229. Founded in February 2008, it's largest shareholder is pankaj mansukh mahidharia with a 30% stake. Intellipharm Limited is a established, micro sized company, Pomanda has estimated its turnover at £120.4k with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Intellipharm Limited Health Check
Pomanda's financial health check has awarded Intellipharm Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 6 areas for improvement. Company Health Check FAQs
1 Strong
3 Regular
6 Weak
Size
annual sales of £120.4k, make it smaller than the average company (£539.4k)
- Intellipharm Limited
£539.4k - Industry AVG
Growth
3 year (CAGR) sales growth of 4%, show it is growing at a similar rate (4.3%)
- Intellipharm Limited
4.3% - Industry AVG
Production
with a gross margin of 23.8%, this company has a higher cost of product (49%)
- Intellipharm Limited
49% - Industry AVG
Profitability
an operating margin of 8.3% make it as profitable than the average company (8.2%)
- Intellipharm Limited
8.2% - Industry AVG
Employees
with 3 employees, this is below the industry average (10)
3 - Intellipharm Limited
10 - Industry AVG
Pay Structure
on an average salary of £36k, the company has an equivalent pay structure (£36k)
- Intellipharm Limited
£36k - Industry AVG
Efficiency
resulting in sales per employee of £40.1k, this is less efficient (£79.7k)
- Intellipharm Limited
£79.7k - Industry AVG
Debtor Days
it gets paid by customers after 119 days, this is later than average (47 days)
- Intellipharm Limited
47 days - Industry AVG
Creditor Days
its suppliers are paid after 48 days, this is slower than average (24 days)
- Intellipharm Limited
24 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Intellipharm Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Intellipharm Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 78.4%, this is a higher level of debt than the average (40.3%)
78.4% - Intellipharm Limited
40.3% - Industry AVG
INTELLIPHARM LIMITED financials
Intellipharm Limited's latest turnover from October 2022 is estimated at £120.4 thousand and the company has net assets of £8.9 thousand. According to their latest financial statements, Intellipharm Limited has 3 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||||||
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | ||||||||||||||
| Interest Payable | ||||||||||||||
| Interest Receivable | ||||||||||||||
| Pre-Tax Profit | ||||||||||||||
| Tax | ||||||||||||||
| Profit After Tax | ||||||||||||||
| Dividends Paid | ||||||||||||||
| Retained Profit | ||||||||||||||
| Employee Costs | ||||||||||||||
| Number Of Employees | 3 | 3 | 3 | 3 | 2 | 1 | ||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,778 | 2,222 | 2,608 | 3,903 | 3,921 | 3,312 | 4,139 | 4,530 | 4,109 | 3,615 | 1,660 | 2,074 | 2,593 | 384 |
| Intangible Assets | 4 | 5 | 5 | 5 | 5 | 5 | 2,071 | 15,004 | 53,641 | |||||
| Investments & Other | ||||||||||||||
| Debtors (Due After 1 year) | ||||||||||||||
| Total Fixed Assets | 1,778 | 2,222 | 2,608 | 3,903 | 3,921 | 3,316 | 4,144 | 4,535 | 4,114 | 3,620 | 1,665 | 4,145 | 17,597 | 54,025 |
| Stock & work in progress | ||||||||||||||
| Trade Debtors | 39,438 | 27,218 | 29,696 | 27,123 | 14,990 | 3,043 | 12,910 | 14,912 | 20,903 | 11,556 | 5,412 | 2,225 | 8,789 | 23,520 |
| Group Debtors | ||||||||||||||
| Misc Debtors | 2,016 | 7,706 | 14,067 | 9,721 | 1,658 | |||||||||
| Cash | 3,287 | 4,328 | 4,182 | 5,105 | 4,069 | 5,303 | 17,236 | 16,988 | 16,833 | 5,688 | ||||
| misc current assets | ||||||||||||||
| total current assets | 39,438 | 27,218 | 29,696 | 27,123 | 20,293 | 15,077 | 17,092 | 20,017 | 24,972 | 30,926 | 32,369 | 20,871 | 25,622 | 29,208 |
| total assets | 41,216 | 29,440 | 32,304 | 31,026 | 24,214 | 18,393 | 21,236 | 24,552 | 29,086 | 34,546 | 34,034 | 25,016 | 43,219 | 83,233 |
| Bank overdraft | ||||||||||||||
| Bank loan | ||||||||||||||
| Trade Creditors | 12,081 | 3,659 | 5,963 | 21,344 | 7,355 | 9,755 | 20,770 | 24,340 | 28,741 | 33,630 | 33,410 | 30,654 | 73,047 | 108,748 |
| Group/Directors Accounts | ||||||||||||||
| other short term finances | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| other current liabilities | 11,217 | 8,462 | ||||||||||||
| total current liabilities | 12,081 | 3,659 | 5,963 | 21,344 | 18,572 | 18,217 | 20,770 | 24,340 | 28,741 | 33,630 | 33,410 | 30,654 | 73,047 | 108,748 |
| loans | ||||||||||||||
| hp & lease commitments | ||||||||||||||
| Accruals and Deferred Income | ||||||||||||||
| other liabilities | 20,247 | 25,000 | 25,000 | |||||||||||
| provisions | ||||||||||||||
| total long term liabilities | 20,247 | 25,000 | 25,000 | |||||||||||
| total liabilities | 32,328 | 28,659 | 30,963 | 21,344 | 18,572 | 18,217 | 20,770 | 24,340 | 28,741 | 33,630 | 33,410 | 30,654 | 73,047 | 108,748 |
| net assets | 8,888 | 781 | 1,341 | 9,682 | 5,642 | 176 | 466 | 212 | 345 | 916 | 624 | -5,638 | -29,828 | -25,515 |
| total shareholders funds | 8,888 | 781 | 1,341 | 9,682 | 5,642 | 176 | 466 | 212 | 345 | 916 | 624 | -5,638 | -29,828 | -25,515 |
| Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | ||||||||||||||
| Depreciation | 832 | 1,034 | 1,132 | 1,027 | 903 | 414 | 519 | 649 | 96 | |||||
| Amortisation | 4 | 2,066 | 16,033 | 38,637 | 38,637 | |||||||||
| Tax | ||||||||||||||
| Stock | ||||||||||||||
| Debtors | 12,220 | -2,478 | 2,573 | 10,117 | 6,257 | -2,161 | -2,002 | -5,991 | -4,720 | 10,490 | 11,250 | -4,906 | -14,731 | 23,520 |
| Creditors | 8,422 | -2,304 | -15,381 | 13,989 | -2,400 | -11,015 | -3,570 | -4,401 | -4,889 | 220 | 2,756 | -42,393 | -35,701 | 108,748 |
| Accruals and Deferred Income | -11,217 | 2,755 | 8,462 | |||||||||||
| Deferred Taxes & Provisions | ||||||||||||||
| Cash flow from operations | ||||||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | ||||||||||||||
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | ||||||||||||||
| Group/Directors Accounts | ||||||||||||||
| Other Short Term Loans | ||||||||||||||
| Long term loans | ||||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||||
| other long term liabilities | -4,753 | 25,000 | ||||||||||||
| share issue | ||||||||||||||
| interest | ||||||||||||||
| cash flow from financing | ||||||||||||||
| cash and cash equivalents | ||||||||||||||
| cash | -3,287 | -1,041 | 146 | -923 | 1,036 | -1,234 | -11,933 | 248 | 155 | 11,145 | 5,688 | |||
| overdraft | ||||||||||||||
| change in cash | -3,287 | -1,041 | 146 | -923 | 1,036 | -1,234 | -11,933 | 248 | 155 | 11,145 | 5,688 |
intellipharm limited Credit Report and Business Information
Intellipharm Limited Competitor Analysis
Perform a competitor analysis for intellipharm limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in HA1 area or any other competitors across 12 key performance metrics.
intellipharm limited Ownership
INTELLIPHARM LIMITED group structure
Intellipharm Limited has no subsidiary companies.
Ultimate parent company
INTELLIPHARM LIMITED
06517653
intellipharm limited directors
Intellipharm Limited currently has 3 directors. The longest serving directors include Mr Pankaj Mahidharia (Aug 2008) and Mr Amish Patel (Aug 2008).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Pankaj Mahidharia | United Kingdom | 54 years | Aug 2008 | - | Director |
| Mr Amish Patel | United Kingdom | 52 years | Aug 2008 | - | Director |
| Mr Nisar Riaz | 54 years | Aug 2008 | - | Director |
P&L
October 2022turnover
120.4k
+35%
operating profit
10k
0%
gross margin
23.8%
+4.68%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
October 2022net assets
8.9k
+10.38%
total assets
41.2k
+0.4%
cash
0
0%
net assets
Total assets minus all liabilities
intellipharm limited company details
company number
06517653
Type
Private limited with Share Capital
industry
70229 - Management consultancy activities (other than financial management)
86900 - Other human health activities
incorporation date
February 2008
age
17
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
October 2022
previous names
bondco 1253 limited (August 2008)
accountant
-
auditor
-
address
lynwood house, 373-375 station road, harrow, HA1 2AW
Bank
-
Legal Advisor
-
intellipharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to intellipharm limited.
intellipharm limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for INTELLIPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.
intellipharm limited Companies House Filings - See Documents
| date | description | view/download |
|---|
